Clinical Trial Update: A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer [Phase 2]

View source ↗

Summary

Results from a Phase 2 study of ramucirumab in gastric and esophageal cancers have been completed and posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Ramucirumab (Cyramza) (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Stomach Cancer, Esophageal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-10-08